Express Mail Label: EV 392131555 US
Date of Deposit: August 2, 2004

Attorney Docket No.: 23254-507

Please type a plus sign (+) in this box [+]

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/626,085
Filing Date	July 24, 2003
First Named Inventor	Dhanoa
Group Art Unit	~~1614~~ 1626
Examiner Name	~~Not Yet Assigned~~ FPowers
Attorney Docket Number	24591-501

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
FTP	C31	Database Caplus on STN, Accession Number 1999:783937, Castelhano, et al., WO/99/62518 A1, CADUE PHARMACEUTICALS CORP. (1999).
FTP	C32	Database Caplus on STN, Accession Number 2000:806616, Horvath, et al., 6,147,085, NEUROGEN CORPORATION (2000).
FTP	C33	International Search Report for PCT/US03/23539, mailing date: July 23, 2004.

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Fiona T. Powers	Date Considered	11/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box [+]

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/626,085
Filing Date	July 24, 2003
First Named Inventor	Becker
Group Art Unit	~~Not Yet Assigned~~ 1625
Examiner Name	~~Not Yet Assigned~~ ROWLS
Attorney Docket Number	24591-501

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
FTP	B1	WO	93/01160	Merck Sharp & Dohme Limited	01/21/93		
FTP	B2	WO	93/01165	Merck Sharp & Dohme Limited	01/21/93		
FTP	B3	WO	93/01169	Merck Sharp & Dohme Limited	01/21/93		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
FTP	C1	Goadsby, et al., "Substance P Blockade with the Potent and Centrally Acting Antagonist GR205171 does not Effect Central Trigeminal Activity with Superior Sagittal Sinus Stimulation", *Neuroscience*, 1998, 86(1):337-343.
	C2	Von Sprecher, et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis", *Drugs*, 1998, 1(1):73-91.
	C3	Hill, R.G., "Role of Receptors in Nociception", *The Tachykinin Receptors*, ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 471-498.
	C4	Maggi, et al., "Tachykinin Receptors and Tachykinin Receptor Antagonists", *J. Auton. Pharmacol.*, 1993, 13(1):23-93.
	C5	Regoli, et al., "Receptors and Antagonists for Substance P and Related Peptides", *Pharmacol. Rev.*, 1994, 46(4): 551-599.
	C6	Maggio, et al., "History of Tachykinin Peptides", *The Tachykinin Receptors*; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 1-21.
	C7	Nakanishi, S., "Mammalian Tachykinin Receptors", *Annu. Rev. Neurosci.*, 1991, 14:123-136.
	C8	Bellucci, et al., "Pharmacological Profiles of the Novel Mammalian Tachykinin, Hemokinin 1", *Br. J. Pharmacol.*, 2002, 135(1):266-274.
	C9	Burcher, et al., "Autoradiographic Localization of Receptors in Peripheral Tissues", *The Tachykinin Receptors*, ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 125-163.
	C10	Krause, et al., "Molecular Biology of Receptors", *The Tachykinin Receptors*; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 165-218.
	C11	Longmore, et al., "Neurokinin Receptors", *Drug News Perspect.* 1995, 8 (1):5-23.
	C12	Kucharczyk, N., "Tachykinin Antagonists in Development", *Exp. Opin. Invest. Drugs*, 1995, 4 (4):299-311.
	C13	Elliott, et al., "Neurokinin Receptor Antagonists", *Exp. Opin. Ther. Pat.*, 1997, 7 (1):43-54.
	C14	Longmore, et al., "Neurokinin-Receptor Antagonists: Pharmacological Tools and Therapeutic Drugs", *Can. J. Physiol. Pharmaco,* 1997, 75:612-621.
	C15	Gerspacher, et al., "Dual Neurokinin NK_1/NK_2 Receptor Antagonists", *Drugs Future*, 1999, 24(8):883-892.
	C16	Kudlacz, et al., "*In Vitro* and *In Vivo* Characterization of MDL 105, 212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonists", *J. Pharmacol. Exp. Ther.*, 1996, 277(2):840-851.
FTP	C17	Ramsey, et al., "Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors", *J. Pharmacol. Exp. Ther.*, 2001 298(1):307-315.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
FTP	C18	Gerspacher, et al., "*N*-[(*R*, *R*)-(*E*)-1-(4-Chloro-benzyl)-3-(2-oxo-azepan-3-ylcarbamoyl)-allyl]-*N*-metheyl-3,5-bis-trifluoromethyl-benzamide: An Orally Active Neurikinin NK_1/NK_2 Antagonist", *Bioorg. Med. Chem. Lett.*, **2000**, 10: 1467-1470.
	C19	Shih, et al., "Design and Synthesis of the Novel and Orally Active Dual NK_1 and NK_2 Antagonist Sch 205528", **Abstract**, *Books of Abstracts.- Am. Chem. Soc.*, **2000**, MEDI-129.
	C20	Bernstein, et al., "Discovery of Novel, Orally Active Dual NK_1/NK_2 Antagonists", *Bioorg. Med. Chem. Lett.*, **2001**, 11: 2769-2773.
	C21	Ting, et al., "Identification of a Novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-methoxyimino)pentyl]-2-oxo-(1,4'-bipiperidine) as a Dual NK_1/NK_2 Antagonist", *Bioorg. Med. Chem. Lett.*, **2002**, 12: 2125-2128.
	C22	Nishi, T., "Synthetic Studies for the Novel Morpholine and Oxazolidine-Based Tachykinin Receptor Antagonists", *Yuki Gosei Kagaku Kyokaishi*, **2002**, 60(7):657-667.
	C23	Ford-Hutchinson, et al., "Novel Therapeutic Strategies for the Treatment of Human Bronchial Asthma", *Drug News Perspect.*, **1992**, 5(9):542-549.
	C24	Geppetti, et al., "New Aspects on the Role of Kinins in Nneurogenic Inflammation", *Can. J. Physiol. Pharmacol.*, **1995**, 73:843-847.
	C25	Advenier, et al., "The Role of Tachykinin Receptor Antagonists in the Prevention of Bronchial Hyperresponsiveness, Airway Inflammation and Cough", *Eur. Respir. J.*, **1997**, 10(8):1892-1906.
	C26	Chapman, et al., "Tachykinins in the Lung", *Drug News Perspect*, **1998**, 11(8):480-489.
	C27	Murai, et al., "Effects of FK224, a Novel Compound NK_1 and NK_2 Receptor Antagonist, on Airway Constriction and Airway Edema Induced by Neurokinins and Sensory Nerve Stimulation in Guinea Pigs", *J. Pharmacol. Exp. Ther.*, **1992**, 262(1):403-408.
	C28	Joos, et al., "The effect of Inhaled FK224, a Tachykinin NK_1 and NK_2 Receptor Antagonist, on Neurokinin A-Induced Bronchoconstriction in Asthmatics", *Am. J. Respir. Crit. Care Med.*, **1996**, 153(6):1781-1784.
	C29	Joos, et al., "Tachykinin Receptors Antagonists: Potential in Airways Diseases", *Curr. Opin. Pharmacol.*, **2001**, 1(3):235-241.
FTP	C30	Gerspacher, et al., "Dual Neurokinin NK_1/NK_2 Antagonists: *N*-[(*R*, *R*)-(*E*)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-*N*-methyl-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-*N*'-methylhydrazinol]-*N*-[(R)-2-oxo-azepan-3-yl]propionamides", *Bioorg. Med. Chem. Lett.*, **2001**, 11(23):3081-3084.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed_____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Fiona T. Powers	Date Considered	11/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.